Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Teresa L. Helsten"'
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Razelle Kurzrock, Scott M. Lippman, Paul T. Fanta, Julio Romero, Lyudmila A. Bazhenova, Teresa L. Helsten, Santosh Kesari, David E. Piccioni, Gregory A. Daniels, Richard B. Schwab, Barbara A. Parker, Maria Schwaederle
By profiling their patients' tumors, oncologists now have the option to use molecular results to match patients with drug(s) based on specific biomarkers. In this observational study, 347 patients with solid advanced cancers and next-generation seque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d38652e4f16dcdeda5f7bb5f11ff928f
https://doi.org/10.1158/1535-7163.c.6538405.v1
https://doi.org/10.1158/1535-7163.c.6538405.v1
Autor:
Razelle Kurzrock, Scott M. Lippman, Paul T. Fanta, Julio Romero, Lyudmila A. Bazhenova, Teresa L. Helsten, Santosh Kesari, David E. Piccioni, Gregory A. Daniels, Richard B. Schwab, Barbara A. Parker, Maria Schwaederle
Supplemental Methods 1) Sequencing: (182 and 236 gene lists) 2)Therapy 3) Matching Score 4) Statistical Analysis (patient's characteristics, study endpoints and definitions, analyses performed);Supplemental Table 1. Patient characteristics; Supplemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72e4f8a450bacecb9c256df081ef4ca4
https://doi.org/10.1158/1535-7163.22506457
https://doi.org/10.1158/1535-7163.22506457
Autor:
Jane Perlmutter, Gillian L. Hirst, A. Jo Chien, Anthony D. Elias, Andres Forero-Torres, Kevin Kalinsky, Julia Wulfkuhle, Ruby Singhrao, Lajos Pusztai, Nola M. Hylton, Richard Schwab, Smita Asare, Laura Sit, Hope S. Rugo, M. Melisko, Judy C. Boughey, Laura J. Esserman, Angela DeMichele, Laura J. van't Veer, Rebecca Shatsky, Scott M. Berry, Lili Du, Christina Yau, Ashish Sanil, D Yee, Adam Asare, Donald A. Berry, Kathy S. Albain, Amy S. Clark, Anne M. Wallace, Rita Nanda, Claudine Isaacs, Hyo S. Han, Denise M. Wolf, E. Petricoin, Minetta C. Liu, Teresa L. Helsten, Jeffrey B. Matthews, Amy Wilson, Erica Stringer-Reasor, Alexandra Thomas, W. Fraser Symmans, Heather Beckwith, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
SSRN Electronic Journal.
The combination of PD-L1-inhibitor durvalumab and PARP-inhibitor olaparib (DOP) in addition to standard neoadjuvant chemotherapy was investigated in the phase II I-SPY2 platform trial of stage II/III HER2-negative breast cancer. Seventy-three HER2-ne